Bend Research

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Manufacturing

Capsugel adds new commercial-scale spray-dried dispersion capacity at Bend Research

Completes first part of planned US$20m expansion at the plant in Oregon, US
Manufacturing

Bend Research to invest US$20m to expand spray-dried dispersion manufacturing

Will be completed and validated by June 2015
Drug Delivery

Capsugel to buy Bend Research

Adding to its dosage forms business
Ingredients

BASF and Bend Research to develop solubility enhancing excipients

Initially focusing on vinylpyrrolidone-based copolymers
Manufacturing

Dow Chemical and Cambrex collaborate to manufacture drug-solubility solution

Builds on the solubilisation partnership between Dow and Bend Research announced in October 2012
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Problem-solving ingredients for complex drugs

Around 40% of new chemical entities fall into class II – low solubility drugs, making them difficult to formulate. Improving the bioavailability of these compounds is a major challenge but the technologies involved could help to extend the lifecycle of many medicines. Manufacturers are also looking to improve palatability and diversify drug delivery routes to increase patient compliance.
Manufacturing

Catalent and Bend to offer oral drug formulation services

Aiming to provide a more efficient path to market
Subscribe now